INTRODUCTION: Probiotic administration seems to be a rational approach to promote maturation of the neonatal immune system. Mutual interaction of the microbiota with the host immune system is critical for the setting of appropriate immune responses including a tolerogenic one and thevmaintenance of homeostasis. On the other hand, our knowledge on the modes of actions of probiotics is still scarce. METHODS: In our study, probiotic strain Escherichia coli O83:K24:H31 (EcO83) was administered to neonates of allergic mothers (AMs; neonates with increased risk for allergy development) within 48 h after the delivery, and the impact of this early postnatal supplementation on allergy incidence and selected immune markers has been analyzed 10 years after the primary EcO83 administration. RESULTS: We have observed decreased allergy incidence in 10-year-old children supplemented with EcO83 (13 of 52 children were allergic) in comparison with non-supplemented children of AMs (16 of 42 children were allergic). The early postnatal EcO83 supplementation appeared to limit the allergy in the high-risk group (children of AMs) compared to that in the low-risk group (children of healthy mothers). Dendritic cells (DCs) in the peripheral blood of EcO83-supplemented children do not differ significantly in cell surface presence of CD83. The immunomodulatory capacity of EcO83 on DCs was tested in vitro as well. Both directly isolated myeloid and in vitro monocyte-derived DCs from cord blood increased CD83 expression together with interleukin (IL)-10 secretion after EcO83 stimulation. The effect of early postnatal EcO83 supplementation on the microbiota composition of 10-year-old children was characterized by next-generation sequencing, and we have not observed significant changes in the microbiota composition of EcO83-supplemented and non-supplemented children at the age of 10 years. CONCLUSIONS: Early postnatal EcO83 supplementation appears to lower allergy incidence in children of AMs. It seems that the beneficial effect of EcO83 is mediated via modulation of DC functional capacities without impacting the microbiota composition. Larger-scale studies will be necessary to confirm these preliminary findings.

Department of Neonatology Institute for the Care of Mother and Child Prague Czechia

Department of Statistical Modelling Institute of Computer Science of the Czech Academy of Sciences Prague Czechia

Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University Prague Czechia

Institute of Immunology and Microbiology 1st Faculty of Medicine Charles University Prague Czechia

Institute of Microbiology Academy of Sciences Prague Czechia

000      

00000naa a2200000 a 4500

001      

bmc23004629

003      

CZ-PrNML

005      

20230704111544.0

007      

ta

008      

230418s2022 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3389/fimmu.2022.1038328 $2 doi

035    __

$a (PubMed)36703968

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Súkeníková, Lenka $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

245    10

$a Effect of early postnatal supplementation of newborns with probiotic strain E. coli O83:K24:H31 on allergy incidence, dendritic cells, and microbiota / $c L. Súkeníková, V. Černý, T. Thon, R. Roubalová, Z. Jirásková Zákostelská, O. Novotná, P. Petrásková, K. Boráková, I. Kocourková, R. Lodinová-Žádníková, Z. Musil, L. Kolářová, L. Prokešová, Z. Valenta, J. Hrdý

520    9_

$a INTRODUCTION: Probiotic administration seems to be a rational approach to promote maturation of the neonatal immune system. Mutual interaction of the microbiota with the host immune system is critical for the setting of appropriate immune responses including a tolerogenic one and thevmaintenance of homeostasis. On the other hand, our knowledge on the modes of actions of probiotics is still scarce. METHODS: In our study, probiotic strain Escherichia coli O83:K24:H31 (EcO83) was administered to neonates of allergic mothers (AMs; neonates with increased risk for allergy development) within 48 h after the delivery, and the impact of this early postnatal supplementation on allergy incidence and selected immune markers has been analyzed 10 years after the primary EcO83 administration. RESULTS: We have observed decreased allergy incidence in 10-year-old children supplemented with EcO83 (13 of 52 children were allergic) in comparison with non-supplemented children of AMs (16 of 42 children were allergic). The early postnatal EcO83 supplementation appeared to limit the allergy in the high-risk group (children of AMs) compared to that in the low-risk group (children of healthy mothers). Dendritic cells (DCs) in the peripheral blood of EcO83-supplemented children do not differ significantly in cell surface presence of CD83. The immunomodulatory capacity of EcO83 on DCs was tested in vitro as well. Both directly isolated myeloid and in vitro monocyte-derived DCs from cord blood increased CD83 expression together with interleukin (IL)-10 secretion after EcO83 stimulation. The effect of early postnatal EcO83 supplementation on the microbiota composition of 10-year-old children was characterized by next-generation sequencing, and we have not observed significant changes in the microbiota composition of EcO83-supplemented and non-supplemented children at the age of 10 years. CONCLUSIONS: Early postnatal EcO83 supplementation appears to lower allergy incidence in children of AMs. It seems that the beneficial effect of EcO83 is mediated via modulation of DC functional capacities without impacting the microbiota composition. Larger-scale studies will be necessary to confirm these preliminary findings.

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a dítě $7 D002648

650    _2

$a novorozenec $7 D007231

650    _2

$a lidé $7 D006801

650    _2

$a Escherichia coli $x fyziologie $7 D004926

650    _2

$a incidence $7 D015994

650    12

$a alergie $x epidemiologie $x prevence a kontrola $7 D006967

650    12

$a mikrobiota $7 D064307

650    12

$a probiotika $7 D019936

650    _2

$a monocyty $7 D009000

650    _2

$a dendritické buňky $7 D003713

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Černý, Viktor, $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia $d 1985- $7 xx0303525

700    1_

$a Thon, Tomáš $u Institute of Microbiology, Academy of Sciences, Prague, Czechia

700    1_

$a Roubalová, Radka $u Institute of Microbiology, Academy of Sciences, Prague, Czechia

700    1_

$a Jirásková Zákostelská, Zuzana $u Institute of Microbiology, Academy of Sciences, Prague, Czechia

700    1_

$a Novotná, Olga $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

700    1_

$a Petrásková, Petra $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

700    1_

$a Boráková, Kristýna $u Department of Neonatology, Institute for the Care of Mother and Child, Prague, Czechia

700    1_

$a Kocourková, Ingrid $u Department of Neonatology, Institute for the Care of Mother and Child, Prague, Czechia

700    1_

$a Lodinová-Žádníková, Rája $u Department of Neonatology, Institute for the Care of Mother and Child, Prague, Czechia

700    1_

$a Musil, Zdeněk $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia

700    1_

$a Kolářová, Libuše $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

700    1_

$a Prokešová, Ludmila $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

700    1_

$a Valenta, Zdeněk $u Department of Statistical Modelling, Institute of Computer Science of the Czech Academy of Sciences, Prague, Czechia

700    1_

$a Hrdý, Jiří $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czechia

773    0_

$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 1038328

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36703968 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230418 $b ABA008

991    __

$a 20230704111541 $b ABA008

999    __

$a ok $b bmc $g 1924991 $s 1190838

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2022 $b 13 $c - $d 1038328 $e 20230109 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405

LZP    __

$a Pubmed-20230418